664 reports of this reaction
3.5% of all SIPONIMOD reports
#3 most reported adverse reaction
DIZZINESS is the #3 most commonly reported adverse reaction for SIPONIMOD, manufactured by Novartis Pharmaceuticals Corporation. There are 664 FDA adverse event reports linking SIPONIMOD to DIZZINESS. This represents approximately 3.5% of all 19,111 adverse event reports for this drug.
Patients taking SIPONIMOD who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is moderately reported among SIPONIMOD users, representing a notable but not dominant share of adverse events.
In addition to dizziness, the following adverse reactions have been reported for SIPONIMOD:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 664 FDA reports for SIPONIMOD. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 3.5% of all adverse event reports for SIPONIMOD, making it one of the most commonly reported side effect.
If you experience dizziness while taking SIPONIMOD, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.